News

Co-led by global investors Insight Partners and M Ventures, the financing round has also seen participation from Gaingels and One Way Ventures. ImmuneBridge is developing allogeneic NK cell-based

The receipt of the drug distribution licence by Hainan Asieris is an important step towards improving drug circulation services, standardising management, and promoting drug imports and distribution in

Located at the TÜBITAK MAM Gebze campus in Kocaeli province close to Istanbul, the MEDIBIYO facility can generate biotechnological drugs and vaccines that align with good manufacturing practice

With regard to the closure of the deal, AcelRx got a total of around $2.7m from Aguettant and Alora. Alora agreed to acquire all assets associated to DSUVIA

It also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The firm raised the amount from Syncona Investment Management, and Cambridge Innovation Capital. Proceeds

The gene therapy is used for the treatment of inherited retinal disease (IRDs) caused by RPE65 mutations. Retina is impacted in patients who suffer from RPE65 mutation-associated IRDs and

Entresto (sacubitril/valsartan) is intended for treating symptomatic chronic heart failure with left ventricular systolic dysfunction in patients who are aged from 1 to <18 years. Novartis global head

As part of the deal, both the entities will be involved in research activities to detect and improve LENSai in silico-generated antibodies. These antibodies are being developed as

The independent bid committee of Sensidose has recommended the cash offer. At present, the shares of Sensidose are listed on Spotlight Stock Market in Sweden. Sensidose is involved